- Home
- GLUE vs BA^A Comparison
GLUE vs BA^A Comparison
Compare GLUE & BA^A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLUE | BA^A |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | N/A |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | GLUE | BA^A |
|---|---|---|
| Price | $16.37 | N/A |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 791.7K | N/A |
| Earning Date | 11-06-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $181,538,000.00 | N/A |
| Revenue This Year | $81.52 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $65.21 | ★ N/A |
| Revenue Growth | ★ 1112.27 | N/A |
| 52 Week Low | $3.50 | N/A |
| 52 Week High | $18.15 | N/A |
Technical Indicators
Market Signals| Indicator | GLUE | BA^A |
|---|---|---|
| Relative Strength Index (RSI) | 59.39 | N/A |
| Support Level | $15.21 | N/A |
| Resistance Level | $17.75 | N/A |
| Average True Range (ATR) | 0.98 | 0.00 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 57.83 | 0.00 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.